This week in therapeutics




Licensing status

Publication and contact information



Follistatin-like 1 (FSTL1)

Mouse and cell culture studies suggest inhibiting FSTL1 could help prevent cancer metastasis to the bone. In mouse and human cancer cell lines, small interfering RNA knockdown of FSTL1 decreased invasiveness and expression of bone metastasis-associated factors compared with no knockdown. In mouse xenograft models of melanoma, siRNA against Fstl1 decreased tumor growth, metastasis to the bone and survival compared with control siRNA. Next steps include developing FSTL1 inhibitors and conducting studies in patient samples to determine whether there is a correlation between elevated FSTL1 levels and bone metastasis.

SciBX 6(37); doi:10.1038/scibx.2013.1024
Published online Sept. 26, 2013

Patent application filed; available for licensing from the Keio University School of Medicine
Contact: Koji Nakamoto,
Keio University School of Medicine, Tokyo, Japan

Kudo-Saito, C. et al. Cancer Res.; published online Aug. 21, 2013;
Contact: Chie Kudo-Saito, Keio University School of Medicine, Tokyo, Japan